The global boom in AI applications is reshaping the biotechnology and healthcare industries, with AI increasingly being used to accelerate drug discovery and development. This shift has fueled a wave of new strategic alliances. Genomics BioSci & Tech. (Genomics) entered the U.S. market in 2023 through its investment in Wyzer, and in 2024, it raised capital for its subsidiary LAI SHI TE SHENG YI, bringing in strategic investors to speed up new drug development. In July this year, Chairman Michael Chou (周孟賢) personally attended a forum announcing a strategic alliance with BIONET Corp., highlighting his determination to accelerate Genomics’ diversification and global expansion.
Read more
